Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.07+0.31 (+0.35%)
At close: 4:00 PM EDT

89.22 0.15 (0.17%)
After hours: 4:46 PM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close88.76
Bid88.87 x 100
Ask89.84 x 100
Day's Range86.91 - 89.24
52wk Range55.00 - 131.33
1y Target EstN/A
Market Cap16.75B
P/E Ratio (ttm)242.04
Avg Vol (3m)1,144,145
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis

    Incyte Corporation today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi® , has been included as a recommended treatment in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for myelofibrosis .

  • Benzingayesterday

    Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98

    Argus raised its price target on shares of Incyte Corporation (NASDAQ: INCY ), premising the positive opinion on a trio of factors. The firm noted that the company reported better than expected second ...

  • Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016
    Capital Cube6 days ago

    Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Incyte Corp. a score of 69. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more (Read more...)